Structural studies on vertebrate and invertebrate acetylcholinesterases and their complexes with functional ligands

Drug Development Research

Volumn 50, Issue 3-4, 2000, Pages 573-583

  Greenblatt, Harry M ^a   Silman, Israel ^a   Sussman, Joel L ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

AChE; Cholinesterase; Ligands

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; INSECTICIDE; LIGAND; MF 268; PHYSOSTIGMINE DERIVATIVE; RIVASTIGMINE; UNCLASSIFIED DRUG;

CRYSTAL STRUCTURE; DROSOPHILA MELANOGASTER; DRUG BINDING; DRUG CONFORMATION; DRUG CONJUGATION; DRUG DESIGN; DRUG SELECTIVITY; ENZYME BINDING; ENZYME INHIBITOR COMPLEX; ENZYME STRUCTURE; NONHUMAN; REVIEW; STRUCTURE ANALYSIS; TORPEDO CALIFORNICA;

EID: 0033809395     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-2299(200007/08)50:3/4<573::aid-ddr41>3.0.co;2-7     Document Type: Review

References (69)

1. Increased neurotoxicity following concurrent exposure to pyridostigmine bromide, DEET, and chlorpyrifos
2. Role of tyrosine 337 in the binding of huperzine A to the active site of human acetylcholinesterase
3. Structure and dynamics of the active site gorge of acetylcholinesterase: Synergistic use of molecular dynamics simulation and X-ray crystallography
4. Kinetic and structural studies on the interaction of the anti-Alzheimer drug, ENA-713, with Torpedo californica acetylcholinesterase
5. 'Back door' opening implied by the crystal structure of a carbamoylated acetylcholinesterase
6. Electrotactins: A class of adhesion proteins with conserved electrostatic and structural motifs
7. A modular treatment of molecular traffic through the active site of cholinesterases
8. Acetylcholinesterase inhibition by fasciculin: Crystal structure of the complex
9. Conformational flexibility of the acetylcholinesterase tetramer suggested by X-ray crystallography
10. Crystal structure of mouse acetylcholinesterase. A peripheral site-occluding loop in a tetrameric assembly
11. Clinical trials of a new anticholinesterase agent, galanthamine, in anesthesiology
12. Trials in the treatment of facial nerve paralysis using nivaline
13. Conformational analyses and molecular-shape comparisons of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase
14. Golden age of insecticide research: Past, present, or future?
15. A cholinesterase genes server (Esther): A data base of cholinesterase-related sequences for multiple alignments, phylogenetic relationships, nmtations and structural data retrieval
16. Relationship between sequence conservation and three-dimensional structure in a large family of esterases, lipases, and related proteins
17. Cation-π interactions in chemistry and biology: A new view of benzene, Phe, Tyr, and Trp
18. Acetylcholine binding by a synthetic receptor: Implications for biological recognition
19. Brain selective inhibition of acetylcholinesterase: A novel approach to therapy for Alzheimer's disease
20. Drosophila acetylcholinesterase: Mechanisms of resistance to organophosphates
21. Isolation and characterization of acetylcholinesterase from Drosophila
22. Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3Å resolution
23. Nivalin in the treatment of residual post-polio paralysis and pseudo-hypertrophic muscular dystrophy
24. Conversion of acetylcholinesterase to butyxylcholinesterase: Modeling and mutagenesis
25. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase
26. Crystal structure of an acetylcholinesterase-fasciculin complex: Interaction of a three-fingered toxin from snake venom with its target
27. The X-ray structure of a transition state analog complex reveals the molecular origins of the catalytic power and substrate specificity of acetylcholinesterase
28. 3D structure of Drosophila melanogaster acetylcholinesterase and of its complexes with putative insecticides
29. The pharmacology of galanthamine and its analogues
30. The rationale for E2020 as a potent acetylcholinesterase inhibitor
31. Identification of a more potent analogue of the naturally occurring alkaloid huperzine A; predictive molecular modeling of its interaction with acetylcholinesterase
32. 3D structure at 2.7Å resolution of native and E202Q mutant human acetylcholinesterase complexed with fasciculin-II
33. Structure of acetylcholinesterase complexed with E2020 (Aricept®): Implications for the design of new anti-Alzheimer drugs
34. Crystal structures of recombinant native and E202Q human acetylcholinesterase complexed with the snake toxin fasciculin-II at 2.8Å
35. The structures of huperzine A and B, two new alkaloids exhibiting marked anticholinesterase activity
36. Inhibitory effect of huperzine B on the cholinesterase activity in mice
37. Anticholinesterases: Medical applications of neurochemical principles
38. Donepezil approved for treatment of Alzheimer's disease
39. Effective charge on acetylcholinesterase active sites determined from the ionic strength dependence of association rate constants with cationic ligands
40. The α/β hydrolase fold
41. Dissection of the human acetylcholinesterase active center - Determinants of substrate specificity - Identification of residues constituting the anionic site, the hydrophobic site, and the acyl pocket
42. Prediction of the binding site of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl] piperidine in acetylcholinesterase by docking studies with the SYSDOC program
43. Prediction of the binding sites of huperzine A in acetylcholinesterase by docking studies
44. Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons
45. Long chain analogs of physostigmine as potential drugs for Alzheimer's disease: New insights into the mechanism of action in the inhibition of acetylcholinesterase
46. DINO: Visualizing structural biology
47. Three distinct domains in the cholinesterase molecule confer selectivity for acetyl- and butyrylcholinesterase inhibitors
48. Site of fasciculin interaction with acetylcholinesterase
49. 3D structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A
50. Identification of amino acid residues involved in the binding of huperzine A to cholinesterases
51. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands
52. Electrostatic attraction by surface charge does not contribute to the catalytic efficiency of acetylcholinesterase
53. Structural and functional studies on acetylcholinesterase: A perspective
54. A preliminary comparison of structural models for catalytic intermediates of acetylcholinesterase
55. Physostigmine, galanthamine and codeine act as 'noncompetitive nicotinic receptor agonists' on clonal rat pheochromocytoma cells
56. Synthesis and structure-activity-relationships of acetylcholinesterase inhibitors - 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds
57. Purification and crystallization of a dimeric form of acetylcholinesterase from Torpedo californica subsequent to solubilization with phosphatidylinositol-specific phospholipase C
58. Atomic structure of acetylcholinesterase from Torpedo californica: A prototypic acetylcholine-binding protein
59. The cholinesterases: From genes to proteins
60. Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo
61. Amino acid residues controlling acetylcholinesterase and butyrylcholinesterase specificity
62. Pharmacological activity of novel anticholinesterase of potential use in the treatment of Alzheimer's disease
63. Anionic subsites of the acetylcholinesterase from Torpedo californica: Affinity labelling with the cationic reagent N,N-dimethyl-2-phenyl-aziridinium
64. Characterization of the acetylcholinesterase gene from insecticide-resistant houseflies (Musca domestica)
65. Drug evaluation of huperzine A in the treatment of senile memory disorders